# US 2004/0018547 A1 · Ion channel receptor and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018547 A1
- Document ID: US20040018547A1
- Status: Published application
- Kind: A1
- Application number: 10/622,896
- Filed: 2003-07-18
- Published: 2004-01-29
- Earliest claimed: 2002-07-19
- Assignees: Regeneron Pharmaceuticals, Inc.
- Inventors: David J. Glass
- Web page: https://patentgrep.com/patent/US20040018547A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MINC102. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MINC102 gene product. The present invention also provides for diagnostic and therapeutic methods for treating muscle atrophy by inhibiting expression or activity of MINC102.

## Claims

### Claim 1

An isolated nucleic acid molecule having a sequence selected from the group consisting of:
(a) SEQ ID NO:1;
(b) a nucleotide sequence that hybridizes under stringent conditions to the complement of the nucleotide sequence of (a) and which encodes MINC102, wherein the stringent conditions are 30% formamide in 5×SSPE (0.18 M NaCl, 0.01 M NaPO4, pH 7.7, 0.001 M EDTA) buffer at a temperature of 42° C. and remaining bound when subject to washing at 42° C. with 0.2×SSPE; or
(c) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleic acid of (a) or (b) and which encodes MINC102.

### Claim 2 (depends on 1)

A human MINC102 protein encoded by the nucleic acid sequence of claim 1.

### Claim 3

A human MINC102 protein comprising SEQ ID NO:2, or biologically active fragments thereof.

### Claim 4

A method for identifying an agent capable of inhibiting the expression or activity of MINC102, comprising:
(a) administering a test agent to an animal expressing a MINC102 protein, or protein fragment; and
(b) determining the ability of the test agent to inhibit MINC102 expression or activity.

### Claim 5 (depends on 4)

The method of claim 4, wherein the MINC102 protein comprises the amino acid sequence of SEQ ID NO:2, or a fragment thereof.

### Claim 6

A therapeutic method for treating, inhibiting, or reducing muscle atrophy in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of inhibiting MINC102 activity or expression.

### Claim 7 (depends on 6)

The therapeutic method of claim 6, wherein the agent is capable of inhibiting MINC102 activity.

### Claim 8 (depends on 7)

The therapeutic method of claim 7, wherein the agent is an antagonist of MINC102.

### Claim 9 (depends on 8)

The therapeutic method of claim 8, wherein the antagonist is an antibody to MINC102.

### Claim 10 (depends on 9)

The therapeutic method of claim 9, wherein the antibody may be polyclonal, monoclonal, chimeric, humanized, or a wholly human antibody.

### Claim 11 (depends on 8)

The therapeutic method of claim 8, wherein the antagonist is an activator of the Akt pathway.

### Claim 12 (depends on 11)

The therapeutic method of claim 11, wherein the antagonist is insulin-like growth factor 1 (IGF-1), clenbuterol, albuterol, or salbuterol.

### Claim 13 (depends on 6)

The therapeutic method of claim 6, wherein the agent is capable of inhibiting MINC102 expression.

### Claim 14 (depends on 13)

The therapeutic method of claim 13, wherein the agent is an antisense molecule, a ribozyme or triple helix, or a short interfering RNA (siRNA) capable of silencing MINC102 gene expression.

### Claim 15

An isolated nucleic acid sequence encoding a mouse MINC102, comprising:
(a) SEQ ID NO:3; or
(b) a nucleotide sequence which, but for the degeneracy of the genetic code, would hybridize to the complement of SEQ ID NO:3, and which encodes a molecule having the biological activity of MINC102.

### Claim 16

A transgenic animal, comprising a modification of an endogenous MINC102 gene.

### Claim 17 (depends on 3)

An antibody which specifically binds the MINC102 protein of claim 3.
